Singapore vs South-East Asia (WHO region): Hypertension: effective treatment coverage (controlled hypertension)
Singapore
38.8%
in 2019
South-East Asia (WHO region)
13.3%
in 2019
Singapore rank
11th
South-East Asia (WHO region) rank
13th
Hypertension: effective treatment coverage (controlled hypertension) over time
- Singapore
- South-East Asia (WHO region)
How they compare
Singapore currently reports 38.8% against 13.3% in South-East Asia (WHO region), a difference of 25.5%.
That makes Singapore's figure about 2.9 times South-East Asia (WHO region)'s.
Across all 30 years both countries report, Singapore has been ahead every year.
Singapore ranks 11th and South-East Asia (WHO region) ranks 13th of 193 countries.
Singapore has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Singapore | South-East Asia (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 6.8% | 2.6% | 4.2% | Singapore |
| 2000s | 16.4% | 5.7% | 10.8% | Singapore |
| 2010s | 32.1% | 10.7% | 21.4% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hypertension: effective treatment coverage (controlled hypertension), Singapore or South-East Asia (WHO region)?
- Singapore, at 38.8% against 13.3% in South-East Asia (WHO region) as of 2019.
- What is the difference in hypertension: effective treatment coverage (controlled hypertension) between Singapore and South-East Asia (WHO region)?
- 25.5%, with Singapore ahead.
- How many years of comparable data are there for Singapore and South-East Asia (WHO region)?
- 30 years are reported by both, from 1990 to 2019.
- How do Singapore and South-East Asia (WHO region) rank globally for hypertension: effective treatment coverage (controlled hypertension)?
- Singapore ranks 11th and South-East Asia (WHO region) ranks 13th of 193 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hypertension: effective treatment coverage (controlled hypertension) among adults aged 30-79 with hypertension, crude (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.